# Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

> **NCT00060996** · PHASE3 · TERMINATED · sponsor: **United Therapeutics** · enrollment: 30 (—)

## Conditions studied

- Critical Limb Ischemia
- Peripheral Vascular Disease
- Foot Ulcers
- Rest Leg Pain

## Interventions

- **DRUG:** Remodulin® (treprostinil sodium) Injection

## Key facts

- **NCT ID:** NCT00060996
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-02
- **Primary completion:** 2004-09
- **Final completion:** 2004-09
- **Target enrollment:** 30 (—)
- **Last updated:** 2013-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00060996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00060996, "Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00060996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*